102.64
14.77 (00.14%)
As of Mar 06, 2024
NOVARTIS AG [NVS]
As of Jan 31, 2024 | Source: Annual Report to the SEC
Company Overview
Novartis is an innovative medicines company. Our purpose is to reimagine medicine to improve and extend people’s lives. Our strategy is to focus on high-value, innovative medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.
| Country | United States |
| Phone Number | 01141613241111 |
| Industry | Chemicals And Allied Products |
| Employees | 25646 |
| CEO | Vasant Narasimhan |
| Website | www.novartis.com |
Recent Stories
Financial Overview
| Revenue | 45,440 M |
| Operating Revenue | 9,769 M |
| Profits | 14,854 M |
| Net Cash | 5,776 M |
Management Effectiveness
| Return on Equity | -1.18% |
| Return on Assets | -0.55% |
| Turnover Ratio | 0.42 M |
| EBIT | 9,769 M |
Profit Ratios
| Gross Margin | 34,188 M |
| Operating Margin | 21.5% |
| Profit as % of Revenues | 230.16% |
| Profit as % of Assets | 13.67% |
| Profit as % of Stockholder Equity | 31.77% |
Balance Sheet and Cash Flow Measures
| Total Assets | 99,945 M |
| Total Liabilities | 53,195 M |
| Operating Cash Flow | 14,458 M |
| Investing Cash Flow | 5,596 M |
| Financing Cash Flow | -14,278 M |